INTRODUCTION
============

Tuberculosis (TB) remains an international health problem. Many efforts have been made to control the disease since it was declared a global emergency 20 yr ago. In 2012, there were estimated 8.6 million new TB cases and 1.3 million TB deaths globally \[[@B1]\]. The increasing incidence of TB due to multidrug-resistant strains of *Mycobacterium tuberculosis* (MDR-TB, defined as resistance to at least rifampin \[RIF\] and isoniazid \[INH\]) is hampering efforts for the control and management of TB \[[@B2][@B3]\]. Among these deaths there were an estimated 170,000 from MDR-TB, a relatively high total compared with 450,000 incident cases of MDR-TB \[[@B1]\].

Globally, an estimated 3.6% of new cases and 20.2% of previously treated cases are due to MDR-TB. The highest levels are in eastern Europe and central Asia, where more than 20% of new cases and more than 50% of previously treated cases involve MDR-TB \[[@B1]\].

Molecular mechanisms of *M. tuberculosis* drug resistance are well known and reported to involve mutations in specific genes. RIF resistance involves mutations in the *rpoB* gene (the 81-bp RIF resistance-determining region \[RRDR\]), and INH resistance is associated with mutation in *inhA* (positions -15 and -8 in the *inhA* promoter sequence), *katG* (codon 315) and other genes \[[@B4][@B5][@B6][@B7][@B8][@B9][@B10]\]. Resistance to ethambutol (EMB), a first-line drug that is used in combination with INH and RIF, involves mutations in *embB* (codon 306) \[[@B11][@B12]\].

Mutations in the 81-bp RRDR of the *rpoB* gene are found in about 96% of RIF-resistant *M. tuberculosis* isolates. Mutations at codon 516, 526, and 531 are among the most frequent mutations in RIF-resistant strains. For INH-resistant clinical isolates, mutations within the *katG* gene occur most frequently between codons 138 and 328, particularly at codon 315, accounting for 50-95%. Mutations at positions -15 and -8 in the *inhA* regulatory region also vary greatly for 6-43%. The *embB* codon 306 mutation is most frequent in clinical isolates resistant to EMB, accounting for as high as 65% resistant strains \[[@B13]\].

Rapid detection of drug resistance to both first- and second-line anti-TB drugs has become a key component of TB control programs. Technologies that allow rapid, cost-effective, and high-throughput detection of specific nucleic acid sequences are required.

There are currently three commercially available PCR-based tests for the rapid detection of drug resistance in TB: the INNO-LiPA Rif-TB (Innogenetics, Zwijndrecht, Belgium), Genotype MTBDRplus (Hain Lifescience GmbH, Nehren, Germany), and Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) assays \[[@B14][@B15][@B16]\].

The Luminex xMAP system (Luminex Corp, Austin, TX, USA) is a multiplexed microsphere-based suspension array platform capable of analyzing and reporting up to 100 different reactions in a single reaction vessel and offers a new platform for high-throughput nucleic acid detection, which is being used in a variety of applications \[[@B17][@B18]\]. This system can rapidly detect multiple DNA sequences and uses microsphere sets coupled to a tag that recognizes and binds the amplicon carrying the specific single nucleotide polymorphism (SNP). Each microsphere set is characterized by a distinct spectral address given by the combination of red and infrared fluorophores within the microspheres. Once bound, the target DNA molecules are fluorescently tagged with streptavidin-R-phycoerythrin, and the microspheres are individually analyzed with a red laser that recognizes the microsphere set and a green laser that provides a quantitative readout of the bound target. Some benefits of suspension array technology include rapid data acquisition, excellent sensitivity and specificity, and multiplexed analysis capability \[[@B19][@B20]\].

This study was undertaken to develop a high-throughput assay based on allele-specific primer extension (ASPE) and MagPlex-TAG microspheres to detect anti-TB drug resistance mutations.

METHODS
=======

1. Bacteria and DNA extraction
------------------------------

The 357 *M. tuberculosis* clinical isolates were obtained from the culture collection at the Korean Institute of Tuberculosis. The laboratory reference strain *M. tuberculosis* H37Rv, which is susceptible to all drugs and which has no mutation in any of the drug-resistant genes, was used as the wild-type control. The 309 of *M. tuberculosis* clinical isolates and H37Rv had the known results for phenotypic drug susceptibility by the absolute concentration method with Lowenstein-Jensen (LJ) medium. Their critical concentrations for resistance were as follows: INH, 0.2 µg/mL; RIF, 40 µg/mL; EMB, 2 µg/mL \[[@B21]\]. Other 48 clinical strains were included in order to further confirm the ability to detect mutations. The sequencing analysis of drug-resistant genes (*inhA* promoter, *katG*, *rpoB*, and *embB*) indicated that the mutation patterns represented the drug-resistant mutation types. A loop of fresh *M. tuberculosis* culture on LJ media was suspended in 400 µL of TE buffer (10 mM Tris-HCl, pH 8.0; 1 mM EDTA) in a screw cap microcentrifuge tube. After boiling the mixture at 100℃ for 15 min, heat-killed bacteria were centrifuged at 16,000g for 1 min, and the extracted DNA was stored at -20℃ for use.

2. Multiplex PCR
----------------

Multiplex PCR reaction consisted of 50 ng genomic DNA, 1× PCR reaction buffer, 1.5 mM MgCl~2~, 200 µM each dNTP, 0.2 µM each primer, and 2.5 Units HotStar Taq polymerase (Qiagen, Hilden, Germany). A non-target PCR negative control was included in each assay run. PCR primer sequences are given in [Table 1](#T1){ref-type="table"}. Amplification condition were as follows according to the protocol by the manufacturer: 95℃ for 15 min; 40 cycles of 94℃ for 30 sec, 55℃ for 30 sec, and 72℃ for 30 sec; and a final extension at 72℃ for 7 min. Samples were kept at 4℃ until use. Multiplex PCR products were analyzed by gel electrophoresis. Four clearly resolved bands ranged in size from 170 to 250 bp under optimum PCR conditions (data not shown).

3. Exonuclease I-Shrimp Alkaline Phosphatase treatment
------------------------------------------------------

Before the ASPE reaction, each PCR reaction was treated with Exonuclease I-Shrimp Alkaline Phosphatase to remove unused primers and nucleotides. To 7.5 µL of the PCR reaction mixture, 3 µL of ExoSAP-IT reagent (Affymetrix, Cleveland, OH, USA) was added. Samples were then incubated at 37℃ for 30 min, followed by 15 min incubation at 80℃ to inactivate the enzyme and kept at 4℃ until use.

4. Multiplex ASPE reaction
--------------------------

Multiplex ASPE reaction was carried out by using 5 µL treated PCR product in a final volume of 20 µL. Each reaction consisted of 1× ASPE buffer (20 mM Tris-HCl, pH 8.4; 50 mM KCl), 1.25 mM MgCl~2~, 0.75 U Tsp DNA polymerase (Invitrogen, Carlsbad, CA, USA), 5 µM dATP, dTTP, and dGTP (Invitrogen), 5 µM biotin-dCTP (Invitrogen), and 25 nM each TAG-ASPE primer. The TAG-ASPE primers were made to target mutations capable of detection by the currently produced kits. The TAG-ASPE primer sequences are listed in [Table 2](#T2){ref-type="table"}, and TAG sequences were provided by Luminex Corp. The ASPE reactions were incubated at 96℃ for 2 min; 40 cycles of 94℃ for 30 sec, 55℃ for 1 min, and 74℃ for 2 min; and kept at 4℃ until use.

5. Hybridization to MagPlex-TAG microspheres
--------------------------------------------

Each hybridization reaction was carried out with 2,500 of each set of the appropriate MagPlex-TAG microspheres (Luminex Corp.) per reaction. The microsphere mixture was diluted in 2× Tm hybridization buffer (0.4 M NaCl, 0.2 M Tris, 0.16% Triton X-100, pH 8.0) to 100 of each microsphere set per microliter and mixed by vortexing and sonication for approximately 20 sec. Twenty five microliters of the MagPlex-TAG microsphere mixture and 20 µL of distilled water were added to each well of a 96-well plate. Five microliters of each ASPE reaction was added directly to each well. The samples were denatured at 96℃ for 90 sec and incubated at 37℃ for 30 min. Samples were pelleted by placing the plate on a magnetic separator and washed twice with 1× Tm hybridization buffer (0.2M NaCl, 0.1 M Tris, 0.08% Triton X-100, pH 8.0). The microspheres were then resuspended in 75 µL of 1× Tm hybridization buffer containing 5 µg/mL streptavidin-R-phycoerythrin (Invitrogen) and incubated for 15 min at 37℃. The reactions were analyzed in 50 µL at 37℃ on Luminex 200 system.

6. Genotyping
-------------

To optimize the microsphere-based TAG-ASPE genotyping method for the detection of first-line anti-TB drug resistance mutations, we performed the TAG-ASPE method and DNA dideoxy sequencing with *M. tuberculosis* H37Rv DNA and obtained the same results by both methods.

Genotyping results obtained by the microsphere-based TAG-ASPE method for all samples were compared with genotyping results obtained by dideoxy dye-terminator sequencing. DNA samples not sequenced for each mutation were excluded from analysis.

7. Data analysis
----------------

The signals (median fluorescence intensity, MFI) generated for each microsphere population were used to assess the sample genotype. The genotype was determined based on the wild or mutant allelic ratio: $$\text{Wild\ type\ allelic\ ratio} = \frac{\text{(NET\ MFI)\ wild} - \text{type\ allele}}{\text{(NET\ MFI)\ wild} - \text{type\ allele} + \text{(NET\ MFI)\ mutant\ allele}}$$ or $$\text{Mutant\ allelic\ ratio}\frac{\text{(NET\ MFI)\ mutant\ allele}}{\text{(NET\ MFI)\ mutant\ allele} + \text{(NET\ MFI)\ wild} - \text{type\ allele}}$$

Once threshold values were set, the allelic ratio was used to discriminate wild type, mutant, and indeterminate.

We calculated sensitivity, specificity, and confidence intervals (CI) of TAG-ASPE method compared with phenotypic drug susceptibility test (DST) by the absolute concentration method with LJ medium.

RESULTS
=======

DNA samples from the 357 clinical isolates and H37Rv were genotyped by both methods ([Table 3](#T3){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}). For the *inhA* gene, 268 wild-type (C) and 90 mutant (T) were observed in the -15 position by both methods. In the -16 position, 358 wild type (A) were observed by both methods. In the -8 position, 344 wild-type (T) and 10 mutant (C) were observed by both methods, and sequencing revealed four other mutants. For the codon 315 in the *katG* gene, 172 wild-type (AGC) and 169 mutant (ACC) were observed by both methods, and sequencing revealed 11 other mutants.

Both methods were performed to confirm mutations in the *rpoB* gene (the 81-bp RIF resistance-determining region \[RRDR\]). In codon 516, 286 wild type (GAC) and 67 mutant (GTC and TAC) were observed by both methods, and sequencing revealed three other mutants. In codon 526, 296 wild-type (CAC) and 44 mutant (TAC and GAC) were observed by both methods, and sequencing revealed 16 other mutants. In the codon 531, 183 wild type (TCG) and 171 mutant (TTG) were observed by both methods, and sequencing revealed two other mutants.

One hundred ninety six wild type (ATG) and 157 mutant (GTG, CTG, ATA, ATC, and ATT) were observed in the codon 306 for the *embB* gene by using both methods. Sequencing also detected one other mutant.

Each wild type or mutant represented ≥0.7 and indeterminate represented 0.3-0.7 allele ratio ranges.

When we compared the TAG-ASPE method with phenotypic DST, the sensitivity and specificity were 83% (95% CI, 79-88%) and 97% (95% CI, 90-100%) for INH. For RIF testing, the sensitivity and specificity were 90% (95% CI, 86-93%) and 100% (95% CI, 99-100%). Also, the sensitivity and specificity were 58% (95% CI, 51-65%) and 86% (95% CI, 79-93%) for EMB ([Table 4](#T4){ref-type="table"}).

DISCUSSION
==========

The Luminex xMAP system is a multiplexed microsphere-based suspension array platform capable of analyzing and reporting up to 100 different reactions in a single reaction vessel. In recent years, xMAP technology has been used increasingly for multiplexed high-throughput nucleic acid detection in research, commercial, and diagnostic molecular laboratory settings. Four genotyping assay methods have used the Luminex xMAP flow cytometer platform: direct hybridization (DH), single-base extension (SBE), ASPE, and oligonucleotide ligation (OL) \[[@B22]\]. Lee et al. \[[@B23]\] compared four flow cytometric SNP detection assays; SBE and ASPE more clearly differentiated each SNP compared with DH and OL. Also, ASPE is more cost-effective and simpler than SBE on the basis of cost and labor. Their study implicated ASPE is a good method for genetic typing, which requires many markers and a high level of multiplexing.

The resistance of *M. tuberculosis* to anti-TB drugs is almost exclusively due to spontaneous mutations in target genes. We chose the ASPE genotyping assay for the detection of first-line anti-TB drug resistance-related genes. For the TAG-ASPE method, mutations used in the commercially available PCR-based diagnostic tests for the *inhA* (position -8, -15, and -16), *katG* (codon 315), *rpoB* (codon 516, 526, and 531) and *embB* (codon 306) genes were targeted and confirmed by sequencing. Some studies reported the detection of mutations in anti-TB drug resistance-related genes with multiplex ligation-dependent probe amplification (MLPA) method and DH in the Luminex xMAP system. Bergval et al. \[[@B24]\] reported a lack of specificity of the *embB*306 MLPA probe of a total of 13 MLPA probes for one allele associated with resistance; the *embB*306 MLPA probe was unable to detect this ATG to ATA codon change. The 16 direct hybridization probes used to detect mutations in anti-TB drug resistance-related genes displayed 100% concordance with sequencing \[[@B25]\].

In this study, INH, RIF, and EMB drug resistance mutations were detected with high sensitivity and specificity for all targeted genes by using the TAG-ASPE method. Also, the results for all 23 TAG-ASPE primers were 100% concordant with those obtained by sequencing. For the non-detected loci, the TAG-ASPE method has an advantage that allows for the entry of new SNPs and/or the removal of unnecessary SNPs in existing assays.

Compared with manual bidirectional dideoxy sequencing or next generation sequencing, the TAG-ASPE method offers shorter analysis time and potentially lower cost \[[@B26]\]. Sequencing the same number of samples is more tedious because multiple PCR reactions are required per genomic sample being analyzed. Analysis of the sequencing data also requires additional time. Even with automated sequencing, manual set-up of the TAG-ASPE method would compete favorably.

The final goal of this study is to develop a high-throughput assay to detect first- and second-line anti-TB drug resistance mutations. The test in this study was successfully developed for first-line anti-TB drugs. The test using the TAG-ASPE method for second-line drugs is in progress.

In conclusion, the microspheres-based TAG-ASPE method permits multiplexed querying of different nucleotides, thereby allowing multiplexing of all alleles of a particular SNP. It is a valuable tool in the highly reproducible, cost-effective, and high-throughput clinical genotyping applications for multiple alleles associated with drug resistance.
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###### Multiplex PCR primer sequences

![](alm-35-487-i001)

  Gene                                    Sequence, 5\' → 3\'
  --------- ----------------------------- -----------------------------
  *inhA*    Forward                       GAG CGT AAC CCC AGT GCG AA
  Reverse   TCC GGT AAC CAG GAC TGA AC    
  *katG*    Forward                       GCG GTC ACA CTT TCG GTA AG
  Reverse   CAA GCG CCA GCA GGG CTC TT    
  *rpoB*    Forward                       TTG ATC AAC ATC CGG CCG GTG
  Reverse   GGG GTT TCG ATC GGG CAC AT    
  *embB*    Forward                       CAT GTC ATC GGC GCG AAT TCG
  Reverse   TGG CAG GCG CAT CCA CAG ACT   

###### TAG-ASPE primer sequences

![](alm-35-487-i002)

  Gene      Target                                        TAG-ASPE primer sequence, 5\' → 3\'
  --------- --------------------------------------------- ---------------------------------------------
  *inhA*    -15 C                                         TTTACAAATCTAATCACACTATACcaccccgacaacctatcg
  -15 T     TACTTAAACATACAAACTTACTCAcaccccgacaacctatca    
  -16 A     TTCTTCATTAACTTCTAATCTTACaccccgacaacctatcgt    
  -16 G     TACACAAACAATCTTTCACAATTTaccccgacaacctatcgc    
  -8 T      CACAACAAATTCTTATTCAATTCAtggcagtcaccccgacaa    
  -8 C      AATCAACACACAATAACATTCATAggcagtcaccccgacag     
  *katG*    315 AGC                                       ATACTTTACAAACAAATAACACACtaaggacgcgatcaccag
  315 ACC   TTAAACAATCTACTATTCAATCACtaaggacgcgatcaccac    
  *rpoB*    516 GAC                                       CTAAATCACATACTTAACAACAAAagctgagccaattcatgga
  516 GTC   TTTATACATATACACAAACTCTCTAgctgagccaattcatggt   
  516 TAC   TACTCAATACTTACTATATTCATCcagctgagccaattcatgt   
  526 CAC   AATTTCTTCTCTTTCTTTCACAATcgctgtcggggttgaccc    
  526 TAC   AACTTTCTCTCTCTATTCTTATTTcgctgtcggggttgacct    
  526 GAC   TTAATACAATTCTCTCTTTCTCTAcgctgtcggggttgaccg    
  531 TCG   TACTTCTTTACTACAATTTACAACcacaagcgccgactgtc     
  531 TTG   TCTCATCTATCATACTAATTCTTTccacaagcgccgactgtt    
  *embB*    306 ATG                                       ATATACTTTACACTTTCAACAAACacggctacatcctgggca
  306 GTG   TCATCACTTTCTTTACTTTACATTcggctacatcctgggcg     
  306 CTG   ACTTACAATAACTACTAATACTCTcggctacatcctgggcc     
  306 ATG   TCTTACTAATTTCAATACTCTTAcggctacatcctgggcatg    
  306 ATA   CTTAAACTCTACTTACTTCTAATTggctacatcctgggcata    
  306 ATT   CTAACTATAATCTTCATACACATAggctacatcctgggcatt    
  306 ATC   ACAATATACATCACTTAAACTTTCggctacatcctgggcatc    

Upper-case letter: TAG sequence, Low-case letter: ASPE primer sequence

Abbreviation: ASPE, allele-specific primer extension.

###### Mutations detected by sequencing and the TAG-ASPE method

![](alm-35-487-i003)

  Gene                           Nucleotide or codon   Number of strains detected by:         Gene                   Nucleotide or codon   Number of strains detected by:                                       
  --------------- -------------- --------------------- -------------------------------- ----- ------ --------------- --------------------- -------------------------------- ----------- ----- ----- ----- ----- ----
  *inhA*          Position -15   C                     268                                    268                                                                                       GAC         13          13
  T                              90                                                     90           CGC                                   7                                                                    
  Position -16    A              358                                                    358                          CTC                                                    4                                   
  G                                                                                                  CAG                                   1                                                                    
  Position -8     T              344                                                    344                          CCC                                                    1                                   
  C                              10                                                     10           CAA                                   1                                                                    
  G                              1                                                                   AAC                                   1                                                                    
  A                              3                                                                   TGC                                   1                                                                    
  Indeterminate                                                                         4            Indeterminate                                                                      16                      
  *katG*          Codon 315      AGC                   172                                    172                                          Codon 531                        TCG         183         183         
  ACC                            169                                                    169          TTG                                   171                                          171                     
  GGC                            1                                                                   TCC                                   1                                                                    
  AAC                            6                                                                   CAG                                   1                                                                    
  ACA                            4                                                                   Indeterminate                                                                      2                       
  Indeterminate                                                                         11                                                                                                                      
  *rpoB*          Codon 516      GAC                   286                                    286                                          *embB*                           Codon 306   ATG   196         196   
  GTC                            37                                                     37           GTG                                   98                                           98                      
  TAC                            30                                                     30           CTG                                   8                                            8                       
  GGC                            2                                                                   ATA                                   31                                           31                      
  CCC                            1                                                                   ATC                                   13                                           13                      
  Indeterminate                                                                         3            ATT                                   7                                            7                       
  Codon 526       CAC            296                                                    296                          ACG                                                    1                                   
  TAC                            31                                                     31           Indeterminate                                                                      1                       

Abbreviation: ASPE, allele-specific primer extension.

###### Drug susceptibility testing by phenotypic DST and TAG-ASPE method

![](alm-35-487-i004)

        Number of strains detected by   Sensitivity% (95% CI)   Specificity% (95% CI)                           
  ----- ------------------------------- ----------------------- ----------------------- ----- ---- ------------ --------------
  INH   29                              281                     73                      227   10   83 (79-88)   97 (90-100)
  RIF   29                              281                     58                      248   4    90 (86-93)   100 (99-100)
  EMB   91                              219                     168                     137   5    58 (51-65)   86 (79-93)

Abbreviations: DST, drug susceptibility testing; ASPE, allele-specific primer extension; CI, confidence interval; INH, isoniazid; RIF, rifampicin; EMB, ethambutol.
